MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
PARSIPPANY, NJ March 28, 2011 — MCP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products has entered into a multi‐year contract‐manufacturing agreement with an undisclosed biotechnology company. MCP will be responsible for manufacturing and supply of a sterile liquid product used in processing biologics.
Stuart Hinchen, president and co‐founder of MCP noted, “We look forward to serving this important customer and see this partnership as another opportunity to demonstrate our customer‐centric approach in the manufacture of quality‐driven products that improve patient health.” Commenting on being awarded this contract, the third multi‐year contract within a three‐month period, Hinchen stated, “Since the purchase of the Rochester, Michigan manufacturing facility in 2007, we have focused on growing our internal infrastructure to support expansion of our contract manufacturing services.
We accomplished this in a short time‐period by focusing our investments in two key areas: our people and our facility. Additionally, our record of cGMP compliance, driven by our experienced Quality and Regulatory Teams continue as an important factor to all customers that we serve. ”
MCP’s Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing clinical and commercial products.
About MCP Pharmaceuticals, LLC
MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectables, biologics, vaccines, ophthalmics and otics for large and small pharmaceutical and biotech organizations.
MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high‐speed filling lines, four lyophilizers and a clinical fill line. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.
MCP has the capability to manufacture small‐scale clinical through large‐scale commercial products. MCP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit jhppharma.com.
Additional Press Releases
 |
MCP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Chief Executive Officer Succession Webpage | PDF Format |
|
MCP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin® Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement Webpage | PDF Format |
|
MCP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits Webpage | PDF Format |
|
MCP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds Webpage | PDF Format |
|
MCP Pharmaceuticals & SpePharm complete purchase of Dantrium® (dantrolene sodium) Webpage | PDF Format |
|
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To MCP Pharmaceuticals Webpage | PDF Format |
Return To Press & News »
